Follicum AB (publ ) right now stories revised prime line knowledge from a Part IIa research of the tissue repairing peptide FOL-005 for the therapy of hair loss (alopecia). The revised knowledge are primarily based on an impartial evaluate that was performed as a consequence of errors detected within the efficiency evaluation offered by the Firm on Might 6, 2021. The revised outcomes present no vital variations in comparison with what was beforehand reported and the Firm stands by the choice to discontinue growth of the product for the therapy of hair loss. Nevertheless, Follicum will proceed to discover alternatives to additional develop FOL-005 in different illness areas.
“Having scrutinized the beforehand communicated research outcomes, our conclusion stays that the corporate shouldn’t allocate extra assets to the event of FOL-005 for the therapy of hair loss. As an alternative, we are going to give attention to our diabetes drug venture, whereas evaluating different alternatives to make the most of our tissue repairing peptides and our distinctive formulation expertise in different illness areas”, says Follicum‘s CEO, Kim Arvid Nielsen.
For additional data, please contact:
Kim Arvid Nielsen – CEO, Follicum AB
Telephone: +46 (0)70 392 1331
Electronic mail: firstname.lastname@example.org
This data is data that Follicum is obliged to make public in line with the EU Market Abuse Regulation. The data was offered by way of the company of the contact individual above, for publication on the 24 June 2021.
About Follicum AB
Follicum AB (Highlight: FOLLI) develops medication primarily based on tissue restore peptides with potential use in a spread of diseaseareas. The corporate’s most superior drug candidate, FOL-005, is run utilizing a singular formulation expertise discovered secure and well-tolerated in a complete Part 2 research performed in collaboration with internationally famend specialist clinics. Within the area of diabetes, a venture is being performed that goals to guard insulin-producing cells from harm, thus lowering the chance for problems. The initiatives have the potential to grow to be so-called first-in-class medicines. For extra data, go to www.follicum.com.
(c) 2021 Cision. All rights reserved., supply Press Releases – English